Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Category list : Cardiovascular agents

Sort by: Newest first Oldest first A-Z Z-A

  • Survey shows that in patients who have taken aspirin as primary prevention, treatment was inappropriate in nearly 11.6% of cases

    Aspirin inappropriately used for CVD prevention in just over 10% of cases Subscription

    29 JAN 2015 15:12
    Comments (1)

    A survey of nearly 70,000 patients taking aspirin for primary prevention has found that, for the overall cohort, treatment was inappropriate in nearly 11.6% of cases.

  • UK deaths from coronary heart disease (CHD) have declined by 60% since the 1970s

    Analysis questions value of primary prevention medication for reducing CHD deaths Subscription

    27 JAN 2015 12:13

    Population-wide approaches to risk-factor control have had a far greater impact on the reduction of deaths from coronary heart disease than use of primary prevention medication.

  • A recent study shows that statin therapy reduced lipid levels by a similar extent in both men and women. In the image, the chemical structure of atorvastatin, a drug from the statin drug class

    Effectiveness of statins similar for men and women Subscription

    20 JAN 2015 9:30

    Incremental reductions in major vascular events with statin therapy is similar in men and women, according to research published in The Lancet.

  • Streptase discontinued Subscription

    19 DEC 2014 15:30

    The licence for all vial sizes of Streptase (streptokinase; CSL Behring) was discontinued on 31 December 2014. Stock will be available to purchase for a further three months or until it runs out. Further information on 01444 447402 or customerserviceuk@cslbehring.com. 

  • The worst outbreak of the fatal haemorrhagic Ebola virus disease started in the West African country Guinea, infected 17,942 individuals and killed 6,388 people as of 16 December

    2014: The Pharmaceutical Journal's news in review Subscription

    18 DEC 2014

    Looking back at some of the biggest news stories from the past year. 

  • Using pharmacists to support statin-prescribing in general practice improves patients’ chances of reaching their cholesterol targets

    Pharmacy-led statin support service in general practice helps patients reach cholesterol targets Subscription

    12 DEC 2014 16:59 By Janna Lawrence

    Using pharmacists to support statin-prescribing in general practice improves patients’ chances of reaching their cholesterol targets and has a lasting effect on the prescribing behaviour of GPs.

  • MURs should target patients with cardiovascular disease from January 2015 Subscription

    10 DEC 2014 10:16

    Community pharmacists will be expected to offer medicines use reviews to patients with cardiovascular disease and those who are at risk from 1 January 2015, national negotiators have confirmed.

  • Amias can be used with ACE inhibitors Subscription

    4 DEC 2014 11:23

    The summary of product characteristics (SPC) for Amias (candesartan cilexetil; Takeda) now states that the product can be used to treat adult patients with heart failure and impaired left ventricular systolic function when angiotensin converting enzyme (ACE) inhibitors are not tolerated or as add-on therapy to ACE inhibitors in patients with symptomatic heart failure, despite optimal therapy, when mineralocorticoid receptor antagonists are not tolerated. Additional warnings related ...

  • Simvastatin inhibits proliferation of tumour cells and induces calcium-dependent apoptosis, study finds

    Simvastatin induces calcium-dependent apoptosis Subscription

    1 DEC 2014 10:33
    Comments (1)

    Simvastatin inhibits proliferation of tumour cells and induces calcium-dependent apoptosis, shows new research published in Journal of Biological Chemistry.

  • Ivabradine recommendations Subscription

    14 NOV 2014 12:03

    The Pharmacological Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has made new recommendations about the use of ivabradine (Procorolan; Servier). A review of the evidence found that, out of patients with coronary artery disease, a subgroup with symptomatic angina treated with ivabridine were at higher risk of cardiovascular death or non-fatal heart attack. Following this review, PRAC has stated that the medicine should only be used for symptom relief of angina, ...

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.